RT Journal Article
SR Electronic
T1 Novel Hyaluronan Formulation Enhances the Efficacy of Boron Neutron Capture Therapy for Murine Mesothelioma
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 907
OP 911
VO 36
IS 3
A1 SASAI, MASAO
A1 NAKAMURA, HIROYUKI
A1 SOUGAWA, NAGAKO
A1 SAKURAI, YOSHINORI
A1 SUZUKI, MINORU
A1 LEE, CHUN MAN
YR 2016
UL http://ar.iiarjournals.org/content/36/3/907.abstract
AB Background: Malignant pleural mesothelioma (MPM) is a refractory cancer of the pleura caused by asbestos exposure. MPM is difficult to treat because it easily disseminates. Boron neutron capture therapy (BNCT) is a radiotherapy in which cancer cells that selectively take up 10Boron-containing compounds are destroyed, and normal cells are uninjured. Hyaluronan (HA) is a ligand of cluster of differentiation 44 (CD44), that is expressed on MPM cells. Materials and Methods: In order to enhance BNCT for MPM tumors, we developed a novel HA-containing 10B (sodium borocaptate: BSH) formulation (HA-BND-S). We examined the efficacy of HA-BND-S using MPM cells and a mouse MPM model. Results: HA-BND-S preferentially bound MPM cells dose-dependently, and increased the cytotoxicity of BNCT compared to BSH in vitro. HA-BND-S administration significantly increased the survival of MPM tumor-bearing mice compared to BSH at the same 10B dosage in BNCT. Conclusion: Modifying BSH with HA is a promising strategy for enhancing the efficacy of BNCT for therapy of MPM.